MiNK Therapeutics, Inc. INKT 深 滬
等待開盤 04-07 09:30:00 美东时间
11.75
+1.060
+9.92%
華盛通- 最 高12.34
- 今 開10.77
- 成交量 6.27万股
- 最 低 10.75
- 昨 收 10.69
- 總市值 5834.93万
- 52周最高 76.00
- 市盈率 靜 --
- 換手率 1.26%
- 52周最低 6.34
- 委 比 28.57%
- 總股本 496.59万
- 歷史最高 221.55
- 量 比 1.17
- 振 幅 14.87%
- 歷史最低 4.632
- 每 手 1
- 風險率 5.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
MiNK Therapeutics Reports Progress in New Treatments for Lung Disease, Cancer and Immune Disorders
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases
03-31 19:32
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?
MiNK Therapeutics stock drops after a 30% rally as investors react to profit taking and a $1.1 million pediatric cancer therapy deal.
03-11 21:24
Why Domo Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Domo Inc (DOMO) stock jumped 48.8% in pre-market trading after beating Q4 earnings expectations by 117.65% and reporting a rise in revenue.
03-11 17:57
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 23.3% to $0.16 during Tues...
03-11 05:06
Market-Moving News for March 10th
NIO: 7% | NIO shares are trading higher after the company reported better-than-expected Q4 financial results, and stronger-than-expected Q1 revenue outlook. VRTX: 10% | Vertex Pharmaceuticals
03-10 19:17
MiNK Therapeutics Signs Pediatric Cancer Therapy Deal With C-Further, Secures About $1.1M Development Funding
MiNK Therapeutics (NASDAQ:INKT) a clinical-stage biopharmaceutical company advancing invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, today announced a strategic collaboration
03-10 17:42
Reported Earlier, MiNK Therapeutics Highlights Depletion Of iNKT Cells In Advanced IPF At Keystone Symposia, Showcasing Potential For Disease-Modifying Therapy
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK's iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a
02-04 16:42
